Submit your email to push it up the queue
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is a leading player in the global pharmaceutical industry, headquartered in the United States. Founded in 1953, the company has made significant strides in various therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. With a commitment to innovation, Janssen is renowned for its core products, such as innovative treatments for cancer and autoimmune disorders, which are distinguished by their efficacy and safety profiles. The company has achieved notable milestones, including the development of groundbreaking therapies that have transformed patient care. Janssen's strong market position is underscored by its extensive research and development efforts, which continue to drive advancements in medicine, making it a trusted name in healthcare worldwide.
How does Janssen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Janssen's score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Janssen Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Johnson & Johnson, any emissions data or climate commitments would be inherited from its parent company. Janssen is aligned with Johnson & Johnson's sustainability initiatives, which include various climate commitments and reduction targets. However, specific reduction targets or achievements for Janssen are not detailed in the available information. The company participates in several industry-standard initiatives, including the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Johnson & Johnson. While no absolute emissions figures are provided, Janssen's commitment to sustainability reflects a broader industry trend towards reducing carbon footprints and enhancing climate resilience. The absence of specific data underscores the importance of ongoing efforts in tracking and reporting emissions as part of corporate responsibility in the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Janssen is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.